India’s pharmaceutical market witnessed the launch of the first wave of generic versions of Novo Nordisk’s GLP-1 weight-loss drugs, with several domestic drugmakers introducing significantly cheaper alternatives. The launch follows the expiry of Novo Nordisk’s patent on semaglutide in India, opening the door for competition in one of the world’s largest pharmaceutical markets.
At least five Indian pharmaceutical companies introduced generic semaglutide products, with prices reportedly up to 80% lower than the original brand. Despite the price competition, Novo Nordisk is betting that its strong brand recognition, technology capabilities, and patient care ecosystem will help it retain a leading position in the rapidly expanding market.
India: A Key Market for Diabetes and Obesity Drugs
India represents a critical opportunity for pharmaceutical companies developing diabetes and weight-management therapies. The country has around 100 million people living with diabetes, while nearly 25% of the population is classified as obese.
At the same time, India is widely known as “the world’s pharmacy”, thanks to its strong generics manufacturing ecosystem. Indian pharmaceutical companies supply around 20% of the world’s off-patent medicines, making the country a major hub for affordable drug production. As a result, the expiry of Novo Nordisk’s patent has triggered rapid entry by domestic manufacturers eager to capture a share of the growing GLP-1 drug market.
Indian Drugmakers Launch Lower-Cost Alternatives
Leading generic manufacturer Sun Pharmaceutical Industries was among the first to launch a generic semaglutide injection, priced at around ₹750 ($8) per weekly dose, or roughly ₹3,400 per month. This pricing is significantly lower than Novo Nordisk’s semaglutide products in India, which retail between ₹8,800 and ₹10,000 per month depending on dosage.
Dr. Reddy’s Laboratories has launched its own semaglutide version for diabetes treatment at approximately ₹4,200 per month. The company also plans to expand the product to international markets, including Canada, Turkey, and Brazil, later this year. According to Deepak Sapra, CEO of Pharmaceutical Services and API at Dr. Reddy’s, the company aims to make GLP-1 therapies accessible to a much wider patient population. “Our goal is to democratize access to GLP-1 drugs worldwide,” Sapra said during a virtual launch event. Dr. Reddy’s is targeting annual sales of 12 million semaglutide pens in the first year, covering multiple markets including India.
More Generic Brands Expected in the Market
Salil Kallianpur, an independent pharmaceutical consultant noted, “This is something that Indian generic players have been preparing for a very long time”. More than 50 brands of generic semaglutide are expected to enter the Indian market in the coming months. However, the number remains relatively limited compared with typical Indian generic launches because GLP-1 drugs are complex to manufacture and require strict quality controls.
Novo Nordisk Relies on Brand Strength and Partnerships
Despite the growing competition, Novo Nordisk remains confident in its ability to maintain a strong position in India. The company reduced the price of its Wegovy obesity drug by 37% in India in December, even before its patent expired, in an effort to remain competitive. According to Vishal Manchanda, pharma sector analyst at Systematix Group, Novo Nordisk could still retain a large share of the market if it maintains a 15–20% price premium over generic versions. Historically, Novo Nordisk has managed to retain market leadership even after patent expirations, particularly in insulin products, where its strong brand reputation and manufacturing scale have helped it outperform generic rivals.
Strategic Launch of New Brands in India
To strengthen its presence further, Novo Nordisk is adopting a multi-brand strategy in the Indian market. The company is launching Wegovy under the brand name Poviztra in partnership with Emcure Pharmaceuticals, while Ozempic will be marketed as Extensior through collaboration with Abbott India. These partnerships are expected to expand distribution through strong physician networks and pharmacy channels, helping Novo Nordisk maintain broad market reach. “This is a classic strategy to protect a premium brand against cheaper generics,” Kallianpur explained, noting that Novo Nordisk is relying heavily on its reputation. He added, “the brand is essentially the moat.”
Competitive Battle for the GLP-1 Market
The arrival of low-cost generic semaglutide in India marks the beginning of an intense price and market share battle in the fast-growing obesity and diabetes drug segment. As reported by cnbc.com, while Indian pharmaceutical companies aim to expand access through affordable alternatives, Novo Nordisk is betting that its innovation, brand trust, and integrated patient care ecosystem will help it remain a dominant player in the global GLP-1 drug market.
